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Abstract
Objective: Investigate the relationship of the tumor volume after preoperative che-
motherapy (TVAPQ) and before preoperative chemotherapy (TVBPQ) with overall survival 
at two and at five years, and lifetime.
Methods: Our sample consisted of consecutive patients evaluated in the period from 1989 
to 2009 in an Onco-Hematology Service. Clinical, histological and volumetric data were 
collected from the medical records. For analysis, chi-square, Kaplan-Meier, log-rank and 
Cox regression tests were used. 
Results: The sample consisted of 32 patients, 53.1% were male with a median age at 
diagnosis of 43 months. There was a significant association between TVAPQ>500mL and 
the difference between the TVBPQ and TVAPQ (p=0.015) and histologic types of risk 
(p=0.008). It was also verified an association between the difference between the TVBPQ 
and TVAPQ and the predominant stromal tumor (p=0.037). When assessing the TVAPQ 
of all patients, without a cutoff, there was an association of the variable with lifetime 
(p=0.013), i.e., for each increase of 10mL in TVAPQ there was an average increase of 2% 
in the risk of death.
Conclusions: Although our results indicate that the TVAPQ could be considered alone as 
a predictor of poor prognosis regardless of the cutoff suggested in the literature, more 
studies are needed to replace the histology and staging by tumor size as best prognostic 
variable.
© 2014 Sociedade de Pediatria de São Paulo. Published by Elsevier Editora Ltda. All rights 
reserved.
*Corresponding author.
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Tamanho tumoral e prognóstico em pacientes portadores de tumor de Wilms
Resumo
Objetivo: Investigar a relação entre o volume do tumor após a quimioterapia pré-opera-
tória (VTPOS) e antes da quimioterapia pré-operatória (VTPRE) com sobrevida geral aos 
dois e cinco anos, e tempo de vida. 
Métodos: A amostra foi composta por pacientes consecutivos avaliados no período de 
1989 a 2009, em um Serviço de Onco-Hematologia. Os dados clínicos, histológicos e vo-
lumétricos foram coletados a partir dos registros médicos. Para análise, utilizou-se dos 
testes qui-quadrado, Kaplan-Meier, log-rank e regressão de Cox.
Resultados: A amostra foi composta de 32 pacientes, 53,1% do sexo masculino, com 
mediana de idade ao diagnóstico de 43 meses. Houve associação significativa entre 
VTPOS>500mL e a diferença entre o VTPRE e VTPOS (p=0,015) e os tipos histológicos de 
risco (p=0,008). Verificou-se também uma associação entre a diferença entre o VTPRE e 
VTPOS e o tumor de predomínio estromal (p=0,037). Quando se avaliou o VTPOS de todos 
os pacientes, sem um ponto de corte definido, observou-se associação desta variável 
com o tempo de vida (p=0,013), isto é, para cada aumento de 10mL no VTPOS, houve um 
aumento médio de 2% no risco de morte.
Conclusões: Embora os resultados indiquem que o VTPOS poderia ser considerado um 
preditor isolado de mau prognóstico, independentemente do ponto de corte sugerido na 
literatura, mais estudos são necessários para substituir a histologia e estadiamento pelo 
tamanho do tumor como melhor variável prognóstica.
© 2014 Sociedade de Pediatria de São Paulo. Publicado por Elsevier Editora Ltda. Todos os 
direitos reservados.
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Introduction
Wilms’ tumor (WT) accounts for about 6% of all cancers of 
children and it is the most common malignant renal tumor 
of childhood. Most are diagnosed before the age of 5, and 
the current expectation is that over 90% of patients will 
have an excellent outcome. The majority of children have 
an asymptomatic and unilateral abdominal mass. Associated 
symptoms may include hematuria and abdominal pain. This 
last feature should alert to the risk of tumor rupture, a 
finding associated with local abdominal recurrence. 
However, large tumors, usually in advanced stages, did not 
present indication of surgical intervention and can benefit 
from preoperative chemotherapy. This may lead to a tumor 
shrinkage and reduce the chance of complications as tumor 
rupture.1-3 
It is now increasingly important to recognize tumors 
requiring minimal therapy in order to reduce the burden of 
treatment and the risk of late effects.4 Currently, the most 
important predictive indicators of recurrence and mortality 
are staging and tumor histology. The most significant unfa-
vorable factors are high stage and the presence of anapla-
sia, especially in the diffuse form, which is highly resistant 
to chemotherapy.5,6 Based on the correlations between the 
histological features after adjuvant chemotherapy and sur-
vival, three prognostic groups of typical renal tumors of 
childhood were discerned in the Société Internationale 
D’oncologie Pédiatrique (SIOP) studies: low-risk, interme-
diate-risk and high-risk tumors. This classification is based 
on the percentage of overall necrosis and the predominant 
cell type in the residual viable tumor.7,8 The high-risk 
tumors are associated with poor response to therapy and 
reduced survival. Furthermore, the influence of tumor 
response to adjuvant chemotherapy in terms of reducing its 
volume has been studied, as demonstrated in the studies 
SIOP 9/German Society of Pediatric Oncology and 
Hematology (GPOH)9,10 and SIOP 93-01/GPOH.11 They raise 
the possibility that the reduction of tumor volume, besides 
the classification of histological types of risk, could serve 
as a new prognostic parameter for the stratification of 
patients at the time of postoperative treatment. Therefore, 
currently only GPOH uses tumor volume as a parameter for 
risk stratification.12,13
The aim of our study was to investigate the relationship 
of the tumor volume after preoperative chemotherapy 
(TVAPQ) and before preoperative chemotherapy (TVBPQ) 
with overall survival at two and at five years, and lifetime.
Method
Our sample consisted of consecutive patients evaluated in 
the period from 1989 to 2009 in an Onco-Hematology 
Service of a reference hospital in southern Brazil. Clinical, 
histological and volumetric data were collected from the 
medical records. All patients underwent the SIOP protocol 
treatment of chemotherapy. This protocol uses neoadju-
vant chemotherapy to reduce the tumor volume and the 
risk of intraoperative rupture.
Tumor volume was calculated according to Weirich et al,9 
using the ellipsoid formula: length × depth × thickness × 
0.523. The TVBPQ was measured by ultrasound and the 
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TVAPQ was measured in nephrectomy specimen. For analy-
sis, the age of the patients was divided into three groups 
(0-23 months, 24-47 months and ≥48 months). 
As for staging, the stages I and II were grouped. Histologic 
types were classified in low, intermediate and high-risk, 
according to the SIOP 2001 cltassification.8 The cases that 
occurred prior to this publication were classified based on 
the pathological descriptions. Epithelial and stromal pre-
dominant tumors and tumors presenting a predominantly 
rhabdomyomatous component were also identified. Tumors 
that either have or have not suffered rupture at time of 
surgery were also listed. The lifetime was defined as the 
time from the end of the treatment until the outcome 
(death or end of study). For the tumor volume, the patients 
were classified according to the reduction between the 
TVBPQ and TVAPQ in: (1) poor response (<40%) and (2) good 
response (≥40%).10 We also evaluated whether patients with 
TVAPQ greater than 500mL had a poorer prognosis, as 
Reinhard et al11 suggested. 
The association between categorical variables was per-
formed using the chi-square test. Survival curves were 
obtained by Kaplan-Meier and compared by log-rank test. 
To evaluate the effect of the quantitative parameters, the 
Cox regression analysis was used. The level of significance 
was set at 5%, and the analyses were performed using SPSS 
version 18.0.
Results
During the assessment period, we identified 32 patients 
with data available on lesion volume, 53.1% of which were 
male, with ages at diagnosis ranging from 6 to 87 months 
(median 43 months). As for the staging, 3.1% were in stage 
I and V each, and 31.3% in stages II, III and IV each. As for 
histology, two patients were classified as low-risk (com-
pletely necrotic tumor after chemotherapy), 27 as interme-
diate-risk, and two as high-risk (one with a predominantly 
blastematous component after chemotherapy and the other 
with diffuse anaplasia). In one patient it was not possible 
to apply the classification from the data described in the 
pathological report. 
Of the patients classified as intermediate risk, three had 
tumors predominantly epithelial, and three stromal. Only 
one patient with tumor of intermediate risk showed a pre-
dominantly rhabdomyomatous histological type. Only one 
patient had tumor rupture at the time of surgery. The 
median TVBPQ was 569.1mL (range 70.6-2,364.2mL) and 
median TVAPQ was 149mL (range 10-1,468mL). Five patients 
(15.6%) had TVAPQ>500mL. Of those patients, three were 
older than 4 years, 3 had stage IV disease, 3 had interme-
diate-risk histology, and 2 high-risk. Only one of those 
patients who had TVAPQ>500mL exhibited tumor with stro-
mal predominance. No patient presented a predominantly 
epithelial tumor or an associated rhabdomyomatous com-
ponent.
There was a significant association between the 
TVAPQ>500mL and histologic types of risk (p=0.008). No 
patient with low risk presented TVAPQ>500mL. Three 
(11.1%) out of 27 patients at intermediate risk and all high-
risk patients exhibited TVAPQ>500mL (Table 1). There was 
also an association between TVAPQ>500mL and the differ-
ence between TVBPQ and TVAPQ (p=0.015). Nine patients 
(28.1%) had low response (<40%). Of those, 4 (44.4%) had 
Table 1 Clinical features in patients with Wilms tumor (n=32) according to the TVAPQ (tumor volume after preoperative 
chemotherapy).
TVAPQ p
<500mL >500mL
Age (months) 0.556
0-23 5 1
24-47 12 1
≥48 10 3
Stage 0.301
I-II 9 2
III-IV 18 3
Histologic types of risk 0.008
Low 2 —
Intermediate 25 3
High — 2
Histology
Epithelial 3 — 0.212
Stromal 2 1 0.142
Rhabdomyomatous 2 2 0.821
Death
At 2 years 7 2 0.604
At 5 years 8 2 0.584
TOTAL 27 5
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Table 2 Clinical features verified among the patients with Wilms tumor (n=32) according to the reduction between the tumor 
volume before preoperative chemotherapy (TVBPQ) and after preoperative chemotherapy (TVAPQ).
Clinical features Tumor volume reduction (n) p
Poor response <40% Good response ≥40%
Age (months) 0.06
0-23 4 2
24-47 2 11
≥48 3 10
Stage 0.776
I-II 4 7
III-IV 5 16
Histologic types of risk 0.092
Low 1 1
Intermediate 6 22
High 2 -
Histology
Epithelial 1 2 0.144
Stromal 2 1 0.037
Rhabdomyomatous 2 2 0.659
Lifetime 
At 2 years 3 6 0.685
At 5 years 3 7 0.657
TOTAL 9 23
TVAPQ>500mL. From the 23 patients who showed a good 
response (71.9%), only one had TVAPQ>500mL (Table 1). 
No significant association was found between the differ-
ence between TVBPQ and TVAPQ and age of patients 
(p=0.06) and histologic types of risk (p=0.092). However, 
there was an association between the difference between 
TVBPQ and TVAPQ and predominantly stromal tumors 
(p=0.037) (Table 2). 
There were nine deaths (28.1%) at two years and 10 
(31.3%) at five years. Six of them died due to complications 
related to the tumor, and four due to occurrence of acute 
myeloid leukemia (AML) some months after the end of the 
treatment with chemotherapy. The lifetime ranged from 0 
to 210 months. The difference between TVBPQ and TVAPQ 
was not associated with death at 2 years (p=0.685), nor at 
5 years (p=0.657) (Table 2 and Fig. 1). Also, TVAPQ>500mL 
was not associated with death at 2 years (p=0.604), nor at 
5 years (p=0.584) (Table 1). However, TVAPQ of all patients 
was assessed, without a defined cutoff point, and there 
was an association of this variable with lifetime (HR=1.002, 
95%CI: 1.001-1.004, p=0.013), i.e., for each increase of 
10mL in TVAPQ, there was an average increase of 2% in the 
risk of death. We did not find association of other variables 
of the study (age, staging and histology) with the survival.
The difference between TVBPQ and TVAPQ was not asso-
ciated with tumor stage (p=0.776). The difference between 
TVBPQ and TVAPQ was not associated to predominantly epi-
thelial histology (p=0.144), nor to predominantly rhabdo-
myomatous histological type (p=0.659) (Table 2). 
No significant associations were found between 
TVAPQ>500mL and age (p=0.556), stage (p=0.301), predom-
inantly epithelial (p=0.212) and stromal types (p=0.142), 
and predominantly rhabdomyomatous histology (p=0.821) 
(Table 1). We could not evaluate the influence of tumor 
rupture over the volume, because it occurred with only one 
patient. 
Discussion
The relationship of the TVAPQ and TVBPQ with survival has 
previously been addressed only by Weirich et al,10 Reinhard 
et al11 and Graf et al.14 In our study, the age of the patients 
was not significantly associated with the difference 
between TVBPQ and TVAPQ. Nevertheless, it can be 
observed that 21 (91.3%) out of 23 patients that showed 
good response to adjuvant treatment were older than 2 
years.
The frequency of histological types observed in the pres-
ent study was similar to that described by Reinhardt et al.11 
According to the authors, the TVAPQ is a prognostic factor 
for intermediate-risk tumors, for which the event-free sur-
vival was 70% for those with volumes greater than 500mL, 
and 93% for those with volumes of less than 500mL. They 
also concluded that this is especially important for the 
mixed and regressive histological types (both of intermedi-
ate risk), which behave as high-risk tumors. These results 
are highlighted in the review recently published by Dome 
et al.13 Despite the small number of patients with low and 
high-risk histologic types in our study, there was a signifi-
cant association between TVAPQ>500mL and histologic 
types of risk. None of the low-risk patients and only 3 
(11.1%) with intermediate risk had a TVAPQ>500mL, in con-
trast to the high-risk patients. This suggests that volumes 
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greater than 500mL tend to fit in cases with high-risk histo-
logical tumors, as well as those with volumes of less than 
500mL tend to fit in the low-risk cases. 
Conversely, Taran et al15 found no statistically significant 
association between histological risk and tumor volume. 
However, their study evaluated a smaller number of 
patients (their sample size was 48 patients) and did not 
specify the different histologic types of risk.
Although we have not demonstrated an association 
between histologic types of risk and the difference between 
TVBPQ and TVAPQ (p=0.092), 21 patients at intermediate 
risk (77.8%) had good response (≥40%) with adjuvant treat-
ment, whereas the patients with high risk had a poor 
response. The association could be demonstrated with stro-
mal predominant tumors (p=0.037). Two of the three cases 
presenting stromal predominant tumor had poor response 
to preoperative chemotherapy, which is expected in those 
cases, as reported by Weirich et al.9 However, although 
these tumors do not respond well to adjuvant treatment, 
they present a good prognosis, like epithelial predominant 
tumors.9,16 In the study of Weirich et al,9 although there was 
a poor response to adjuvant chemotherapy in most tumors 
of epithelial and stromal predominance, none relapsed. 
According to Verschuur et al,16 the median volume reduc-
tion after pre-operative chemotherapy was significantly 
lower for stromal predominant tumors (33%) as compared 
to other intermediate-risk lesions (67%). As already stated 
by Beckwith et al,17 these features illustrate the indepen-
dence of aggressiveness and responsiveness in determining 
the outcome for some patients with cancer. It is worth 
mentioning that although we did not find a significant asso-
ciation between the predominantly rhabdomyomatous his-
tology and the variables TVAPQ>500mL and the difference 
between TVBPQ and TVAPQ (probably due to the presence 
of only one patient with this feature in our sample), previ-
ous reports from SIOP trials have shown that this differen-
tiation in the stromal type of WT has a good outcome.18
Reinhard et al11 found a 5-year event-free survival rate 
of 91%, but the present study showed a 5-year event-free 
survival rate of 71%. This difference can be explained by 
the fact that our sample included patients with metastatic 
disease (stage IV), while the study of Reinhard et al11 
included children with localized disease. 
Although we found that patients with tumor volumes 
greater than 500mL did not show a better response to adju-
vant chemotherapy, a significant association between 
TVAPQ>500mL and prognosis was not observed, unlike 
Reinhard et al11 and Graf et al.14 In the study by Reinhard et 
al,11 patients with TVAPQ greater than 500mL exhibited a 
worse outcome than those with smaller tumors (70% versus 
93% in 5-year event-free survival). Graf et al14 evaluated 
only patients in non-anaplastic stages II and III of WT and 
verified that time of recurrence and overall survival were 
univariately and multivariately associated with tumor vol-
ume at surgery. 
However, other authors, as Taran et al,15 found that 
tumor volume did not affect survival time. Perhaps our 
findings are related to the fact that few (five) patients had 
TVAPQ>500mL. However, without setting a TVAPQ cutoff, 
every increase of 10mL in volume increased the risk of 
death in 2%. TVAPQ was the only variable statistically asso-
ciated to the prognosis. Thus, the use of TVAPQ without a 
cutoff was the better approach to verify the probability of 
death in our sample, as already stated by Graf et al.14 Our 
data, in accordance with Weirich et al,9,10 Reinhard et al11 
and Graf et al,14 show that TVAPQ could be used as a con-
Figure 1 Difference between TVBPQ and TVAPQ and lifetime.
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tributing factor in the risk stratification of patients submit-
ted to treatment. This aspect is currently being verified in 
the study protocol SIOP 2001 with intermediate-risk 
patients.13
As showed in the results, the difference between TVBPQ 
and TVAPQ was not associated to death at 2 and 5 years. 
Weirich et al10 verified that patients who presented a 
reduction in TVAPQ<40% had a statically significant relapse-
free survival (74.3%) and 5-year survival (80.4%).
Four patients of our sample presented and died of AML a 
few months after the end of treatment. Leukemia has been 
described as a late effect that may lead to death.19 The risk 
of developing leukemia is higher during the first 5 years 
following WT diagnosis. Its frequency is highest among 
those diagnosed after 1990 and it may reflect modifications 
in the treatment protocols, which decrease the use of radi-
ation therapy and increase the intensity of chemotherapy.20
Although our results indicate that the TVAPQ could be 
considered alone as a predictor of poor prognosis regardless 
of the cutoff suggested in the literature, more studies are 
needed to replace the histology and staging by tumor size 
as best prognostic variables. The histology of the viable 
tumor remaining after preoperative chemotherapy, whose 
evaluation was impaired in our study due to the sample 
size, is still considered the best parameter for risk stratifi-
cation of patients, together with staging, as showed by 
Weirich et al,9 Reinhard et al11 and Graf et al.14 More stud-
ies, comprising a larger numbers of patients, are needed to 
prove these findings.
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